BARBED vs. STANDARD Suture for Colporrhaphy at the End of Laparoscopic Hysterectomy (BARD)

November 15, 2023 updated by: Stefano Uccella, Universita di Verona

Barbed Versus Standard Suture for Vaginal Cuff Closure After Total Laparoscopic Hysterectomy: a Randomized Controlled Trial

Hysterectomy is one of the most common surgical procedures performed worldwide, with more than 400,000 hysterectomies performed annually in the United States. As a consequence, even uncommon complications can affect large numbers of patients. Among potentially life-threatening events, vaginal cuff dehiscence complicates 0.14-1.38% of procedures, and any vaginal cuff complications (dehiscence, hematoma, bleeding, infection) are estimated to affect 4.7-9.8% of patients. In this scenario, any preventive strategy can provide clinically relevant benefits. Regarding colporrhaphy, only the adoption of a laparoscopic approach instead of a vaginal approach is supported by high-quality evidence. Our group demonstrated that the laparoscopic closure of the vaginal cuff after total laparoscopic hysterectomy reduces the incidence of vaginal cuff complications.

Among other potentially effective interventions, the use of barbed sutures was associated with a lower incidence of vaginal cuff dehiscence than the standard suture. In a recent meta-analysis, the use of barbed sutures has been associated with a pooled incidence of vaginal cuff dehiscence of 0.4% versus 2% after a traditional vaginal suture. However, this evidence is limited because most pooled studies were retrospective, and only two were randomized controlled trials. Moreover, these two randomized controlled trials had a very small sample size and were not powered to detect clinically relevant differences. On that basis, despite the promising utility of barbed sutures for vaginal cuff closure after total laparoscopic hysterectomy, the choice of the type of suture is not evidence-based but still guided by personal opinions, as well as by the preference and habits of the operators.

Therefore, this study aims to investigate whether the laparoscopic vaginal cuff closure with barbed suture determines a lower incidence of vaginal cuff dehiscence and complications than conventional sutures after total laparoscopic hysterectomy.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

1614

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Verona, Italy, 37125
        • AOUI Verona - University of Verona - Department of Obstetrics and Gynecology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients undergoing elective total laparoscopic hysterectomy
  • Surgery performed for the treatment of benign pathology
  • Age > 18 years
  • Surgery performed by laparoscopy
  • Signature of informed consent

Exclusion Criteria:

  • Patients undergoing emergent surgery
  • Patients candidates for hysterectomy for oncological indication
  • Patients who underwent previous radiation therapy
  • Patients allergic to the suture material used in the study
  • Patients unable to express adequate informed consent to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Colporrhaphy with barbed absorbable suture
The colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)
After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)
Active Comparator: Colporrhaphy with standard absorbable suture
The colporrhaphy will be performed using a standard 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)
After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vaginal cuff dehiscence
Time Frame: 30 days after surgery
Any partial or total separation of the vaginal cuff
30 days after surgery
Vaginal cuff dehiscence
Time Frame: 90 days after surgery
Any partial or total separation of the vaginal cuff
90 days after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
30-day post-surgical morbidity
Time Frame: 30 days after surgery
Perioperative (intraoperative and postoperative) complications graded based on the Clavien-Dindo classification
30 days after surgery
Vaginal cuff complications
Time Frame: 30 days after surgery
Hematoma, abscess, infections, bleeding, resuture of the vaginal cuff
30 days after surgery
Vaginal cuff complications
Time Frame: 90 days after surgery
Hematoma, abscess, infections, bleeding, resuture of the vaginal cuff
90 days after surgery
Hospital stay
Time Frame: From the date of hospital admission to the date of hospital discharge.
Days of hospitalization from the day of admission to the day of discharge.
From the date of hospital admission to the date of hospital discharge.
Operative time
Time Frame: During surgery
Time between first incision and skin closure
During surgery
Intraoperative blood loss
Time Frame: During surgery
Total blood aspirate during the surgical procedure
During surgery
Quality of life index
Time Frame: 90 days after surgery
The Short Form 12 Health Survey (SF-12) investigates 8 different health aspects. Physical activity, role and physical health, role and emotional state, and mental health are measured by two questions. The SF-12 scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
90 days after surgery
Sexual function
Time Frame: 90 days after surgery
The female sexual function index (FSFI) consists of 19 multiple-choice items that assess female sexual functioning based on 6 domains: desire, arousal, orgasm, pain, sexual satisfaction, and lubrication. The total score ranges from 0 to 36, with 26.55 as the cut-off suggesting the presence of sexual dysfunction. The higher the score, the better the sexual function.
90 days after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Stefano Uccella, MD, PhD, Universita di Verona
  • Principal Investigator: Simone Garzon, MD, Universita di Verona
  • Principal Investigator: Pier Carlo Zorzato, MD, Universita di Verona

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2024

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

April 1, 2023

First Submitted That Met QC Criteria

April 15, 2023

First Posted (Actual)

April 27, 2023

Study Record Updates

Last Update Posted (Estimated)

November 16, 2023

Last Update Submitted That Met QC Criteria

November 15, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vaginal Cuff Complications

Clinical Trials on Laparoscopic colporrhaphy with 0-caliber barbed absorbable suture

3
Subscribe